Synlogic, Inc. (NASDAQ:SYBX) Sees Significant Drop in Short Interest

Synlogic, Inc. (NASDAQ:SYBX) was the target of a large decline in short interest in January. As of January 15th, there was short interest totaling 7,729 shares, a decline of 25.7% from the December 31st total of 10,406 shares. Based on an average daily trading volume, of 14,860 shares, the short-interest ratio is presently 0.5 days. Currently, 0.1% of the company’s stock are sold short. Currently, 0.1% of the company’s stock are sold short. Based on an average daily trading volume, of 14,860 shares, the short-interest ratio is presently 0.5 days.

Synlogic Price Performance

SYBX remained flat at $0.63 on Friday. The company’s stock had a trading volume of 7,077 shares, compared to its average volume of 244,894. The stock’s 50-day moving average is $1.10 and its 200 day moving average is $1.42. Synlogic has a 12-month low of $0.54 and a 12-month high of $1.96. The firm has a market cap of $7.37 million, a PE ratio of -2.42 and a beta of 0.39.

Synlogic (NASDAQ:SYBX) last issued its quarterly earnings results on Thursday, November 13th. The biotechnology company reported ($0.19) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.08). Equities analysts expect that Synlogic will post -2.71 EPS for the current fiscal year.

Institutional Trading of Synlogic

A hedge fund recently bought a new stake in Synlogic stock. Citadel Advisors LLC acquired a new position in shares of Synlogic, Inc. (NASDAQ:SYBX) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 29,011 shares of the biotechnology company’s stock, valued at approximately $49,000. Citadel Advisors LLC owned about 0.25% of Synlogic as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 63.40% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Synlogic in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has an average rating of “Sell”.

About Synlogic

Synlogic, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout.